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Abstract
Background: This study was conducted to follow plasma concentrations of sFlt-1 and sKDR, two
soluble forms of the vascular endothelial growth factor (VEGF) receptor in patients undergoing
coronary artery bypass graft (CABG) surgery with extracorporeal circulation (ECC).
Methods: Plasma samples were obtained before, during and after surgery in 15 patients scheduled
to undergo CABG. Levels of sFlt-1 and KDR levels were investigated using specific ELISA.
Results: A 75-fold increase of sFlt-1 was found during cardiac surgery, sFlt-1 levels returning to
pre-operative values at the 6th post-operative hour. In contrast sKDR levels did not change during
surgery. The ECC-derived sFlt-1 was functional as judge by its inhibitory effect on the VEGF
mitogenic response in human umbilical vein endothelial cells (HUVECs). Kinetic experiments
revealed sFlt-1 release immediately after the beginning of ECC suggesting a proteolysis of its
membrane form (mFlt-1) rather than an elevated transcription/translation process. Flow cytometry
analysis highlighted no effect of ECC on the shedding of mFlt-1 on platelets and leukocytes
suggesting vascular endothelial cell as a putative cell source for the ECC-derived sFlt-1.
Conclusion:  sFlt-1 is released during CABG with ECC. It might be suggested that sFlt-1
production, by neutralizing VEGF and/or by inactivating membrane-bound Flt-1 and KDR
receptors, might play a role in the occurrence of post-CABG complication.
Introduction
Coronary artery bypass graft (CABG) surgery with extra-
corporeal circulation (ECC) is associated with an inflam-
matory response because, among numerous other causes,
of blood contact with the artificial bypass surface, cold
cardiac ischaemia and hypothermia [1-3]. Various studies
have highlighted alterations in lipidic, cytokine and hae-
matopoietic colony stimulating factor (CSF) networks
during and after CABG surgery [4-10]. Thus, circulating
levels as platelet-activating factor, leukotriene B4, throm-
boxane B2, interleukin (IL)-6, IL-8, IL-10, soluble IL-1
receptors, soluble tumour necrosis factor alpha (TNF-α)
receptors, macrophage-CSF (M-CSF) and granulocyte-CSF
(G-CSF) are altered during and after surgery and might be
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involved in the post-CABG multiple organ failure syn-
drome. It is now clear that these productions did not
reflect an unspecific inflammatory state since levels of IL-
4, IL-13, leukemia inhibitory factor, GM-CSF, and soluble
IL-6 receptors remain unchanged during and after cardiac
surgery [6,8,9].
The angiogenic network is also affected during and after
CABG [10]. Among angiogenic growth factors, vascular
endothelial growth factor (VEGF) fulfils a central role in
the formation and function of blood vessels and during
vascular healing in response, for example, to vascular
trauma induced by mechanical disruption [11,12]. VEGF
has been characterized as a heparin binding angiogenic
growth factor displaying high specificity for endothelial
cells. The expression of VEGF is stimulated in response to
hypoxia and by a wide range of inflammatory cytokines.
In vivo VEGF induces angiogenesis as well as permeabili-
sation of blood vessels and play central role in the regula-
tion of vasculogenesis [13]. VEGF receptor (VEGFR)
family consists of three members Flt-1 (VEGFR-1), KDR
(VEGFR-2) and Flt-4 (VEGFR-3), all of which belong to
the receptor tyrosine kinase superfamily [13]. Flt-1 and
KDR exhibited high affinity for VEGF. Flt-4 is closely
related in structure to the products of the Flt-1 and KDR
genes. However, VEGF did not show specific binding for
Flt-4 and its expression is restricted to developing lym-
phatic vessels. Soluble forms of the Flt-1 (sFlt-1) and KDR
(sKDR) are found in human plasma [13]. Studies high-
lighted that soluble form of receptors are capable of
sequestering ligand and preventing signal transduction.
Excessive placental sFlt-1 production, by neutralizing
VEGF, may play a causal role in the pathogenesis of the
maternal preeclampsia [14]. Studies reported an associa-
tion between coronary artery disease or myocardial infarc-
tion and elevated circulating levels of VEGF [15,16]. Of
interest, reduced circulating levels of sFlt-1 were found in
these patients suggesting lost of the endogenous compen-
satory anti-inflammatory mechanism induced by sFlt-1.
Strengthening this hypothesis, sFlt-1 was recently
reported to attenuate sepsis morbidity and mortality in an
experimental mouse model by improving both cardiac
and lung functions as compared with untreated animals
[17]. Whether circulating VEGF levels are affected after
CABG [10,18,19], no data are currently available concern-
ing values of its soluble receptors. This study was con-
ducted to elucidate whether sFlt-1 and sKDR were released
during CABG with ECC.
Patients and methods
The investigation conforms with the principles outlined
in the Declaration of Helsinki. Fifteen patients scheduled
to undergo CABG were included in this study. All patients
had a preoperative ejection fraction above 40%. Anaesthe-
sia was induced and maintained with titrated doses of fen-
tanyl and flunitrazepam. Muscular relaxation was
achieved with pancuronium (0.1 mg/kg). Membrane oxy-
genators were used. The blood was harvested from the sur-
gical field and from the cell saver at the end of ECC and
reinfused to all patients. All patients received high doses
of aprotinin. Plasma samples were collected from the
radial artery catheter before vascular cannulation and after
opening the chest (T0), at the end of ECC just before (T1)
and after cross clamp release (T2), after weaning from ECC
(T3), at the 6th (T4) and 24th post-operative hour (T5). All
patients had uneventful surgery. Plasma samples were col-
lected between January 1995 and December 1996 [4] and
were stored at -80°C until sFlt-1 and sKDR assays.
In another set of experiments, an in order to test more pre-
cisely the kinetic of sFlt-1 release, blood samples were har-
vested from a new set of 10 patients before ECC (T0),
immediately at the beginning of ECC before aortic cross
clamp (T1') or after aortic cross clamp (T2'). Leukocytes
and platelets were counted in a haemocytometer. Blood
mononuclear cells were recovered on a Ficoll gradient in
order to extract their RNA contents. Aliquots of blood
were immediately used for flow cytometry analysis of
membrane Flt-1 (mFlt-1) on platelets, monocytes, lym-
phocytes and granulocytes. Plasma samples were stored at
-80°C until sFlt-1 and sKDR assays.
A decrease of plasma protein contents was observed dur-
ing and after CABG surgery [1]. In order to avoid the influ-
ence of haemodilution during bypass, plasma sFlt-1 and
sKDR levels were expressed by pg per mg of total plasma
protein contents (pg/mg) measured at the simultaneous
times. The proteinemia was determined by the BCA Pro-
tein Assay Reagent (Pierce, Rockford, IL). Plasma sFlt-1
and sKDR levels were measured with commercially ELISA
kits (R&D Systems, Abingdon, UK). Biological results
were expressed by pg/mg of protein measured at the
simultaneous times. The sensitivity of the assays enables
the detection of levels as low as 20 pg/ml and 30 pg/ml for
sFlt-1 and sKDR, respectively. Results are expressed as
mean ± SEM.
Blood mononuclear cells were separated on a Ficoll gradi-
ent (400 × g, 20 min) and washed two times with Hanks'
balanced salts solution (HBSS). Total RNA was extracted
with Tri Reagent® (Ambion, Austin, TX). Reverse transcrip-
tion (RT) was performed with 2.5 μg total RNA with the
SuperScript reverse transcriptase (Invitrogen, Cergy Pon-
toise, France). Polymerase chain reaction (PCR) experi-
ments for sFlt-1 transcripts were carried out with a sense
primer 5'-TGTCAATGTGAAACCCCAGA-3' and an anti-
sense primer 5'-GTCACACCTTGCTTCGG AAT-3' which
amplify a 175 bp fragment of the human sFlt-1 gene.
Amplification of glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was performed to confirm the integrity ofJournal of Cardiothoracic Surgery 2007, 2:38 http://www.cardiothoracicsurgery.org/content/2/1/38
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RNA. The GAPDH sense and anti-sense primers were 5'-
GGCTGAGAACGGGAAGC TTG-3' and 5'-GGATGATGT-
TCTGGAGAGCC-3', amplifying a 439 bp fragment. cDNA
was denatured 180 sec at 94°C, and then submitted to 40
cycles consisting in 94°C/60 sec, 58°c or 60°C (for
sVEGFR-1 and GAPDH, respectively)/60 sec and 72°C/75
sec. Products were then analysed on an agarose gel stained
with ethidium bromide. sFlt-1 PCR products were cloned
in Topo™ cloning kit (Invitrogen) and sequenced by the
dideoxynucleotide method on an ABI Prism 310 DNA
genetic analyzer (Applied Biosystems, Foster City, CA).
The presence of mFlt-1 was tested by direct immunofluo-
rescence staining of whole blood (acid-citrate-dextrose-
anticoagulated) using fluorochrome-conjugated antibod-
ies. Briefly 50 μl of whole blood were incubated with 20
μl of mouse IgG1 anti-human Flt-1 conjugated with phy-
coerythrin (PE) or irrelevant mouse IgG1 PE-conjugated
isotype control (R&D systems, Minneapolis, MN) for 30
min at 4°C. Red blood cells were lysed, washed in PBS
buffer, and samples were incubated with anti-CD45 PC7
labelled antibodies. After washing, cells were then submit-
ted to flow cytometric analysis (XL II, Coulter, Margency,
France). Platelets, lymphocytes, monocytes and granulo-
cytes were identified based on the typical morphology in
the forward scatter/side scatter cytogram and with the
CD45 labelling.
Human umbilical vein endothelial cells (HUVECs) were
purchased from Promo Cell (Heidelberg, Germany).
HUVECs were grown in the media provided by the vendor
and cultures were routinely used between passages 4 and
7. HUVECs (2 × 103 cells) in 100 μl of growth media were
plated into 96-well plates and cultured for 3 days at 37°C
in 5% CO2 in air. HUVECs were cultured in the presence
or absence of 10 ng VEGF (PeproTech, London, UK), 10
μl of plasma collected during ECC (T2) and/or 0.25 μg
rabbit anti-soluble Flt-1 (Zymed Laboratories, San Fran-
cisco, CA). Cell proliferation (in sixplicates) was meas-
ured by a colorimetric method using MTS (Promega,
Madison, WI). The MTS tetrazolium compound is biore-
duced by cells into a colored formazan product that is sol-
uble in tissue culture medium. This conversion is
accomplished by NADPH or NADH produced by dehy-
drogenase enzymes in metabolically active cells. In some
experiments the number of cultured cells (in quadrupli-
cate) was directly evaluated using a haemocytometer.
Results are expressed as mean ± SEM. Statistical analysis
was done using Mann-Whitney U-test. A p < 0.05 was con-
sidered significant.
Results
Initial concentrations of plasma VEGF of these patients
were evaluated at 3 pg/mg [10]. As shown in Figure 1A, a
75-fold increase of plasma sFlt-1 concentrations was
found during CABG surgery. Levels increased significantly
(p = 0.0001) during ECC (234.2 ± 16.2 pg/mg), reached
maximum values at the end of ECC before cross clamp
release (446.0 ± 49.3 pg/mg) and returned to pre-opera-
tive values (5.9 ± 2.7 pg/mg) at the 6th post-operative hour
(5.1 ± 0.8 pg/mg). Raw data of plasma sFlt-1 levels were
301.6 ± 135.6 pg/ml and 14915.0 ± 1629.2 pg/ml before
ECC (T0) and at the end of ECC (T2), respectively. In con-
Plasma sFlt1 and sKDR levels during and after cardiopulmo- nary bypass graft surgery Figure 1
Plasma sFlt1 and sKDR levels during and after cardi-
opulmonary bypass graft surgery. A: Plasma sFlt-1 values 
are expressed in pg per mg protein. T0: before vascular can-
nulation and after opening the chest; T1: during extracorpor-
eal circulation (ECC); T2: at the end of ECC before cross 
clamp release; T3: after cross clamp release; T4: the 6th post-
operative hour; T5: the 24th post-operative hour. Mean ± 
SEM of 15 patients. *p < 0.001 as compared with T0 (Mann-
Whitney U-test). B: Plasma sKDR levels are expressed in pg/
mg protein. Same blood sampling time than in A. Mean ± SEM 
of 15 patients. *p < 0.001 as compared with T0 (Mann-Whit-
ney U-test). No statistical differences were observed (Mann-
Whitney U-test). C: Plasma sFlt-1 values at the beginning of 
ECC. T0: before vascular cannulation and after opening the 
chest; T1': before cross clamp; T2': after cross clamp. Mean ± 
SEM of 10 patients. *p = 0.0002 as compared with T0 (Mann-
Whitney U-test).Journal of Cardiothoracic Surgery 2007, 2:38 http://www.cardiothoracicsurgery.org/content/2/1/38
Page 4 of 7
(page number not for citation purposes)
trast to sFlt-1, plasma sKDR levels did not significantly (p
> 0.2) change during and after CABG surgery (Fig. 1B). As
shown in Figure 1C, sFlt-1 levels significantly (p = 0.0002)
increased immediately after the beginning of ECC.
We then investigated if white blood cells might be puta-
tive cellular sources for the ECC-derived sFlt-1 synthesis.
In a first set of experiments sFlt-1 transcripts were evalu-
ated in blood mononuclear cells of patients before and
during ECC. PCR experiments did not reveal differences
for sFlt-1 transcript levels before and after initiation of
ECC (Figure 2, upper panel). The release of sFlt-1 was
recently reported through proteolysis of its membrane
form [20]. In a second set of experiments we, thus, evalu-
ated the effect of ECC on mFlt-1 expression on circulating
blood cell types (i.e; monocytes, lymphocytes, granulo-
cytes and platelets). As shown in Figure 2A (lower panel),
forward scatter and side scatter were used to identify plate-
lets and leukocytes. Figure 2B illustrates the gates used to
characterize lymphocytes, monocytes and granulocytes
among CD45+  cells. ECC had no effect on the basal
expression of mFlt-1 on granulocytes, platelets, lym-
phocytes and monocytes (Figures 2C, 2D, 2E and 2F,
respectively).
sFlt-1 was released during ECC. We then investigated the
activity of the ECC-derived sFlt-1 on the VEGF mitogenic
response in HUVECs by using a colorimetric method. As
shown in Figure 3A, ECC-derived sFlt-1 markedly inhib-
ited the VEGF mitogenic response in HUVECs; the effect
being abolished by the use of anti-sFlt-1 antibodies. Cell
counts (Figure 3B) confirmed the effect of the ECC-
derived sFlt-1 on the growth of VEGF-stimulated
HUVECs.
Discussion
VEGF was first characterized as a potent endothelial
growth factor and stimulator of endothelial permeability.
Studies highlighted that sFlt-1 is capable of sequestering
VEGF and preventing signal transduction [13]. Moreover,
sFlt-1 can act as an endogenous VEGF inhibitor not only
by sequestering VEGF but also by binding and inactivating
membrane-bound Flt-1 and KDR receptors through a
mechanism involving receptor homodimerisation or het-
erodimerisation [21]. The presence of sFlt-1 in serum and
plasma of healthy donors strongly suggest that sFlt-1
might have an important function in the fine regulation of
VEGF mediated activities in vivo. Beside its effect on
endothelial permeability, VEGF is also reported to exhibit
several pro-inflammatory and procoagulant activities [22-
24]. Data have demonstrated elevated VEGF levels follow-
ing CABG surgery [10,18,19], suggesting that VEGF is a
component of the inflammatory network after open heart
surgery. In this study we showed a dramatic (up to 75-
fold) increase of circulating sFlt-1 levels during ECC. In
contrast sKDR levels were unchanged strengthening the
idea that sFlt-1 release is not only the consequence of an
unspecific release in response to cardiac surgery. The ECC-
derived sFlt-1 is functional as judged by its effect in the
VEGF-induced proliferation of HUVECs. The cell source
and the mechanism of these elevated levels of sFlt-1
remain speculative. During the past decade sFlt-1 was
reported to be generated by an alternative splicing of the
mFlt-1 transcript [13]. In our study, sFlt-1 levels peaked
during ECC returning to pre-operative levels at the 6th post
operative hours. This rapid kinetics of production does
not fit well with an elevated transcription, translation
and/or maturation process. Two hypothesises might, thus,
be suggested. The first one is the presence of pre-existing
intracellular pool of sFlt-1 that might be released upon
cell stimulation. The presence of intracellular pool of sol-
uble Toll-like receptors and tumour necrosis factor alpha
(TNF-α) receptors have been already described [25,26].
Of interest, the presence of KDR intracellular pools have
been recently reported in endothelial cells [27], suggesting
the putative existence of similar Flt-1 ones. The second
hypothesis is a proteolysis process. Numerous transmem-
brane cell surface proteins exist as soluble forms suggest-
ing that their cleavage and release from the cell surface
represent a rapid and efficient post-translational regula-
tory mechanism. The proteolytic solubilisation of the lig-
and-binding cytokine receptor ectodomains not only
renders cells insensitive toward cytokine effects. The
capacity of soluble receptor forms to bind their ligands
may prevent the cytokine binding to cell-bound receptors.
Soluble receptors for leukocyte and endothelial cell acti-
vation molecules (Fas ligand, CD40, CD93), for cytokine
receptors (IL-1, IL-2, IL-6, TNF-α), for adhesion and loco-
motion molecules (CD44, CXCL16, ICAM-1, VCAM-1),
for cell-to-cell adhesion molecules involved in endothe-
lial diapedesis (PECAM-1, VE-cadherin), and for growth
factors (bFGF, PDGF) are released by proteolysis by a wide
array of enzymatic activities including neutrophil-derived
serine proteases, secretases (sheddases), metalloproteases
and ADAMs [28-30]. In our study, flow cytometry analysis
did not highlight any effect of ECC on mFlt-1 levels on
white blood cells and platelets. Recently a γ-secretase-
dependent Flt-1 intramembrane proteolysis was found in
vascular endothelial cells reporting, for the first time, a
shedding contribution for the sFlt-1 receptor [20]. The
ectodomain shedding of mFlt-1 on vascular endothelial
cells might, thus, be a putative mechanism explaining the
rapid release of sFlt-1 in blood during ECC. Of interest
serine proteases, metalloproteases and ADAM are acti-
vated during cardiopulmonary bypass [31-33].
Conclusion
sFlt-1 is released during CABG with ECC. The precise
mechanisms of this sFlt-1 production remain to be eluci-
dated. The existence of pre-existing intracellular endothe-Journal of Cardiothoracic Surgery 2007, 2:38 http://www.cardiothoracicsurgery.org/content/2/1/38
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RT-PCR analysis of sFlt-1 transcripts and mFlt-1 on blood mononuclear cells before and during ECC Figure 2
RT-PCR analysis of sFlt-1 transcripts and mFlt-1 on blood mononuclear cells before and during ECC. A: PCR 
experiments were carried out to amplify a 175 bp fragment of the human sFlt-1 receptor. GAPDH amplification (a 439 bp frag-
ment) was performed to highlight the integrity of blood mononuclear cell mRNA. PCR products were analysed on a 1.2% aga-
rose gel. Sizes of PCR products and DNA ladder are indicated by arrows. One representative experiment out of three is 
shown. B: Blood samples were collected before and during ECC. Forward scatter (FS) and side scatter (SS) were used to iden-
tify platelets and leukocytes (A). CD45 expression was used to separate lymphocytes, monocytes and granulocytes (B). Flow 
cytometry revealed no significant effect of ECC on mFlt-1 expression on platelets (C), lymphocytes (D), monocytes (E) and 
granulmocytes (F). The solid line represents blood cells before ECC staining with Flt-1-PE antibodies. The shaded area repre-
sents blood cells during ECC staining with Flt-1-PE antibodies. One experiment representative of 3 is shown.Journal of Cardiothoracic Surgery 2007, 2:38 http://www.cardiothoracicsurgery.org/content/2/1/38
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lial pool of sFlt-1 that might be released upon cell
stimulation or the shedding of endothelial mFlt-1 may be
two putative mechanisms. At this time the physiologic
meaning of these elevated sFlt-1 levels remains specula-
tive. It might be suggested that sFlt-1 production, by neu-
tralizing VEGF and/or by inactivating membrane-bound
Flt-1 and KDR receptors, might play a role in the occur-
rence of post-CABG complications. Investigation of sFlt-1
levels in patients with post-CABG complications would be
of interest to test this hypothesis. If the release of sFlt-1 is
benefit to reduce post-CABG complications sFlt-1 might
became a potential target for preoperative intervention in
the form of sFlt-1 pharmacologic therapy to prevent or
ameliorate some postoperative complications of CABG by
interfering very early in the VEGF-induced inflammatory
cascade rather than later when the number of proinflam-
matory molecules and their associated damages are
greater. Animal models have still highlighted the interest
of sFlt-1 administration in order to reduce disease severity
in experimental inflammatory diseases and sepsis
[17,34,35]. Finally, the activation of VEGFR-1 is essential
for recruitment of adult stem cells. Endothelial progeni-
tors are mobilized into the circulation after CABG [36].
During CABG it is possible that the increase concentration
of sFlt-1 could affect the recruitment of endothelial cell
progenitors with adverse effects on cardiac physiology
after bypass procedure. Strengthening this hypothesis
decrease and dysfunction of endothelial progenitor cells
have been found in umbilical cord blood with maternal
pre-eclampsia; these alterations being associated with the
increased sFlt-1 levels in the umbilical cord blood [37].
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